Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It study
is a multi-center, nonrandomized, open-label, pilot Phase II investigation of PNT2258 to
characterize anti-tumor activity and collect safety data on patients with relapsed or
refractory lymphoma.